Vimarsana
Biggest News Aggregation in the World

Page 38 - Human Use News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Human Use. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Human Use Today - Breaking & Trending Today

Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance - Vimarsana News

Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance

2023 Sets Stage for Future Growth Potential: Completed Seagen Acquisition, Creating World-Class Oncology Organization; Launched Significant Number of New Products and Indications; and Realigned...

Multiple Myeloma Therapeutics Market Expected to Reach - Vimarsana News

Multiple Myeloma Therapeutics Market Expected to Reach

PALM BEACH, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Recent reports show that the Multiple myeloma Diagnostic market will...

Immutep Quarterly Activities Report Q2 FY24 - Vimarsana News

Immutep Quarterly Activities Report Q2 FY24

Media Release Excellent clinical data reported from TACTI-002 Phase II trial, including median Overall Survival of 35.5 months in first line non-small cell lung cancer patients expressing PD-L1...

Trimetazidine: What is the drug that Russian figure skater Kamila Valieva tested positive for? - Vimarsana News

Trimetazidine: What is the drug that Russian figure skater Kamila Valieva tested positive for?

What exactly is the drug that triggered a high-profile doping scandal and eventually led to Valieva's ban and disqualification?

Source: wdsu.com
Takeda's HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Region - Vimarsana News

Takeda's HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Region

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan 29, 2024--